This study plans to learn more about the effectiveness of the TearRestore eyelid warming mask on signs and symptoms of Meibomian Gland Dysfunction (MGD). MGD is a leading cause of dry eye symptoms. Warm compresses are a standard treatment recommended by physicians to treat those diagnosed with MGD. The study will investigate whether the TearRestore mask affects meibomian gland function and dry eye symptoms.

The study will evaluate the effectiveness of the TearRestore eyelid warming mask on signs and symptoms of MGD. Warm compress treatments have been recommended as part of the standard of care by eye physicians, and are an important means in treating MGD. However, current treatment options suffer from varied temperature maintenance and poor compliance. The TearRestore™ mask offers patients a unique experience through providing sustained heat and the ability to see throughout the treatment, which will improve efficacy through improved compliance. If shown to be effective in altering Meibomian gland secretions at a single visit, this novel treatment could potentially offer the millions of patients suffering from MGD a more convenient and effective way to treat the condition.

Inclusion Criteria:

• Adult participants (age 18-89) of any race, gender or ethnicity, diagnosed with meibomian gland dysfunction
• Symptom score greater than eight on the SPEED questionnaire
• Less than 75nm lipid layer thickness (LLT) utilizing the Lipiview II
• Less than 10 second tear break up time (average of 3 measurements)

Exclusion Criteria:

• Participants with less than 6/15 meibomian glands yielding liquid secretions in either eyelid
• Diagnosed with a systemic autoimmune condition including but not limited to Sjogren's or Lupus